Sevoflurane and Dexmedetomidine's Contrasting Renal Impacts After Non-Cardiac Surgery

Not Applicable

Completed

• Conditions: AKI - Acute Kidney Injury
• Interventions: Drug: Sevoflurane inhalant product; Drug: Dexmedetomidine

• Registration Number: NCT06835010
• Lead Sponsor: Tanta University

Brief Summary

Postoperative acute kidney injury (PO-AKI) is a significant complication, especially after complex surgeries. The choice of anesthetic may influence PO-AKI risk. While sevoflurane (SEVO) has been associated with potential renal risks, dexmedetomidine (DXM) has demonstrated renoprotective effects in various surgical settings. These protective effects may be linked to DXM's immunomodulatory properties and influence on the redox balance. Given the common use of SEVO in major non-cardiac surgery and the potential for renal vulnerability, particularly in the elderly, this study hypothesizes that perioperative DXM infusion in patients undergoing major non-cardiac surgery with SEVO anesthesia will reduce the incidence and severity of PO-AKI, especially in those with pre-existing or borderline renal dysfunction.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-20
• Primary Completion: 2024-03-01
• Study Completion: 2024-03-30
• Status Verified: 2025-02
• Study First Submitted: 2025-02-09
• Study First Submitted QC: 2025-02-13
• Last Update Submitted: 2025-02-13
• Study First Posted: 2025-02-19
• Last Update Posted: 2025-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

• Patients who were assigned for TKR surgery;
• Patients with preoperative serum creatinine (SCr) levels of <1.1 mg/ml;
• Patients with controlled medical conditions;
• Patients free of exclusion criteria were enrolled in the study.

Exclusion Criteria

• Male patients were excluded to guard against the impact of senile prostatic hypertrophy on kidney functions;
• Patients who had preoperative SCr of >1.1 mg/dl;
• Presence of any urological disorders, urological stone diseases;
• Patients with autoimmune diseases, medical disorders requiring maintenance on immunosuppressant therapy;
• Patients with cancer anywhere in the body were excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SEVO Group	Sevoflurane inhalant product	-
DXM Group	Dexmedetomidine	-
DXM Group	Sevoflurane inhalant product	-

Primary Outcome Measures

Name	Time	Method
Percentage Difference in Serum Creatinine levels After Dexmedetomidine Administration in Total Knee Replacement surgery under sevoflurane anesthesia.	5 months	The study assesses the mean percentage difference of serum creatinine levels in patients who was undergoing total knee replacement under sevoflurane anesthesia with Dexmedetomidine infusion (using standard laboratory assays).

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, El Gharbyia, Egypt